OncoMatch/Clinical Trials/NCT06848699
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Is NCT06848699 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for solid tumor cancer.
Treatment: HLX43 dose 1 · HLX43 dose 2 · HLX43 dose 3 · HLX43 dose 4 · HLX43 dose 5 · Serplulimab — The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR mutation
Disease stage
Required: Stage IV
Metastatic disease required
advanced /metastatic solid tumor...at least one measurable lesion assessed by the investigator according to RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: egfr tyrosine kinase inhibitor
Must have received: platinum-based chemotherapy
Lab requirements
Blood counts
Major organ functions are normal, meeting the following criteria (within 14 days prior to the first administration in this study, no transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) treatment was received)
Kidney function
Major organ functions are normal, meeting the following criteria (within 14 days prior to the first administration in this study, no transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) treatment was received)
Liver function
Major organ functions are normal, meeting the following criteria (within 14 days prior to the first administration in this study, no transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) treatment was received)
Cardiac function
No NYHA class II or higher heart failure or LVEF <50%; no unstable angina; no myocardial infarction or cerebrovascular accident within the past 6 months (excluding lacunar infarction, minor cerebral ischaemia, or transient ischaemic attack); no uncontrolled arrhythmia (including QTc interval ≥450 ms for males and ≥470 ms for females, with QTc interval calculated using the Fridericia formula); no poorly controlled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite active treatment)
Major organ functions are normal, meeting the following criteria (within 14 days prior to the first administration in this study, no transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) treatment was received)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06848699 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received egfr tyrosine kinase inhibitor and platinum-based chemotherapy.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify